Description

Simple

Clinical

Overview

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Pharmacology

Indication

Investigated for use/treatment in macular degeneration.

Pharmacodynamic

Information currently not available.

Mechanism of action

Fenretinide inhibits the growth of several human cancer cell lines, acting through both retinoid-receptor-dependent and retinoid-receptor-independent mechanisms.1In vivo, fenretinide selectively accumulates in breast tissue and is particularly active in inhibiting rat mammary carcinogenesis.1 An imp... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

"Mechanism of fenretinide (4-HPR)-induced cell death"

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Fenretinide
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Chlormadinone
The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Fenretinide.
Clomocycline
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Fenretinide is combined with Clomocycline.
Cyproterone acetate
The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Fenretinide.
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fenretinide.
Demeclocycline
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Fenretinide is combined with Demeclocycline.
Demegestone
The therapeutic efficacy of Demegestone can be decreased when used in combination with Fenretinide.
Desogestrel
The therapeutic efficacy of Desogestrel can be decreased when used in combination with Fenretinide.
Dienogest
The therapeutic efficacy of Dienogest can be decreased when used in combination with Fenretinide.
Diethylstilbestrol
The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Fenretinide.
Doxycycline
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Fenretinide is combined with Doxycycline.
Drospirenone
The therapeutic efficacy of Drospirenone can be decreased when used in combination with Fenretinide.
Eravacycline
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Fenretinide is combined with Eravacycline.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fenretinide.
Estradiol
The therapeutic efficacy of Estradiol can be decreased when used in combination with Fenretinide.
Estradiol cypionate
The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Fenretinide.
Estradiol valerate
The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Fenretinide.
Ethinylestradiol
The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Fenretinide.
Ethynodiol diacetate
The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Fenretinide.
Gestodene
The therapeutic efficacy of Gestodene can be decreased when used in combination with Fenretinide.
Gestrinone
The therapeutic efficacy of Gestrinone can be decreased when used in combination with Fenretinide.
3 References
  1. 1 . Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S: Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol. 2008 Sep;62(4):655-65. Epub 2007 Dec 8.PubMed: 18066548
  2. 2 . Takahashi N, Watanabe Y, Maitani Y, Yamauchi T, Higashiyama K, Ohba T: p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action. Int J Cancer. 2008 Feb 1;122(3):689-98.PubMed: 17955489
  3. 3 . Simeone AM, Tari AM: How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci. 2004 Jun;61(12):1475-84.PubMed: 15197471